Zacks: Analysts Set $24.50 Target Price for Surface Oncology Inc (SURF)
Surface Oncology Inc (NASDAQ:SURF) has received a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.
Analysts have set a twelve-month consensus price objective of $24.50 for the company and are anticipating that the company will post ($0.68) earnings per share for the current quarter, according to Zacks. Zacks has also given Surface Oncology an industry rank of 107 out of 255 based on the ratings given to its competitors.
Several equities analysts recently commented on the company. Zacks Investment Research upgraded Surface Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday. Robert W. Baird assumed coverage on Surface Oncology in a research report on Tuesday, September 18th. They set an “outperform” rating and a $23.00 target price for the company. Finally, Cowen restated a “buy” rating on shares of Surface Oncology in a research report on Tuesday, August 14th.
Surface Oncology (NASDAQ:SURF) last announced its quarterly earnings data on Tuesday, August 14th. The company reported ($0.73) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.76) by $0.03. The firm had revenue of $2.43 million during the quarter. On average, equities research analysts forecast that Surface Oncology will post -2.38 EPS for the current year.
Several institutional investors have recently bought and sold shares of the stock. Northern Trust Corp bought a new position in shares of Surface Oncology during the 2nd quarter worth approximately $1,294,000. Bank of New York Mellon Corp bought a new position in shares of Surface Oncology during the 2nd quarter worth approximately $248,000. Millennium Management LLC bought a new position in shares of Surface Oncology during the 2nd quarter worth approximately $8,723,000. Bank of America Corp DE bought a new position in shares of Surface Oncology during the 2nd quarter worth approximately $1,317,000. Finally, Laurion Capital Management LP bought a new position in shares of Surface Oncology during the 2nd quarter worth approximately $326,000. Institutional investors and hedge funds own 63.32% of the company’s stock.
Surface Oncology Company Profile
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27.
Featured Article: Google Finance Portfolio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.